Navigation Links
Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics
Date:10/28/2009

On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.

Newtown, PA (PRWEB) October 28, 2009 -- On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.
   
MAGI, a regional specialty distributor that covers 25 percent of the U.S., will augment Quotient's direct sales force by promoting the company's products and facilitating the order process within its territory, which will create access to key customer markets throughout the Midwest. Unlike many specialty distribution organizations, MAGI is ISO 13485:2003 certified and specializes in representing companies in blood, anesthesia, vascular access, respiratory, NICU/PICU, interventional and critical care areas of the acute care hospital setting.

For customers in the rest of the country, Quotient will sell products through its direct sales force and has signed an agreement with the Global Healthcare Exchange (GHX) to provide electronic order processing in all regions outside the Midwest. As a member of GHX, Quotient is now linked with 3800 hospitals nationwide for electronic order processing and invoicing allowing greater efficiency and reduced administration costs versus typical paper processing.

"This exclusive selling agreement partners us with a highly accomplished and experienced team to bring Quotient's transfusion diagnostics products to our customers in the Midwest," said Jeremy Stackawitz, President and CEO, Quotient Biodiagnostics. "MAGI's proven success in hospital blood banks and high level of customer service is a strong match with Quotient's strategic principles. Combined with GHX, Quotient is now well positioned to service accounts nationwide."

Quotient Biodiagnostics was formed earlier this year to directly commercialize its proprietary line of products under the trade name ALBAclone®. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.

This first BLA includes products used in forward blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-D, Anti-E, and Anti-c, as well as some rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Lea, Anti-Leb, and Anti-Lub - all monoclonal antibodies. Quotient also has two specialty products in its initial portfolio including the ALBAclone® Advanced Partial RhD Typing Kit which identifies weak and partial RhD types with result comparable to molecular analysis at a fraction of the cost, and the Quant-Rho® FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. In addition, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete a full portfolio of manual reagents of nearly 60 products.

"MED Alliance Group is excited about the opportunity to represent Quotient Biodiagnostics. We believe our specialty sales force, which has been promoting solutions to blood bank and blood center customers for over ten years, will embrace Quotient Biodiagnostics' technologies and diligently represent them to our customers," said Michael Crawford, Chief Operating Officer, MED Alliance Group, Inc.

Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.quotientbd.com, or call the customer service line 888-284-1901, or e-mail customer.service(at)quotientbd.com.

About Quotient Biodiagnostics
Quotient Biodiagnostics is the diagnostics division of Quotient Bioscience Group (United Kingdom), and through its wholly owned subsidiary, Alba Bioscience, brings over 30 years experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group's world leading range of blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3123734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market
2. MedAppz Signs Agreement with MedAssets to Offer SAAS-based Electronic Health Record to MedAssets' Non-acute Customers
3. Chimps Show Signs of Culture
4. Pumping Up the Volume in the Face to Reduce Signs of Aging
5. Vicon Signs License Agreement with Microsoft to Develop New Medical Technology
6. Vicon signs license agreement with Microsoft to develop new medical technology
7. Capital BlueCross Reaches Out to Former Employees of Turbine Airfoil Designs
8. Pluromed, Inc. Signs Agreement with Boston Scientific
9. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
10. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
11. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare ... conditions, announced today that the Company will present its ... on Tuesday, February 16, 2016, at 4:30 p.m. ET.  ... overview of its business and growth strategy, as well ... 31, 2015. --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development of a once-daily, oral therapy for ... Chief Medical Officer, Dr. Maya Halpern , has notified ... Chief Medical Officer and from its Board of Directors ... reaching retirement age. Allen Baharaff . Mr. ...
(Date:2/11/2016)... , February 11, 2016 ... Autoclave Market Report 2016 research report provides information ... regions, development status with crucial statistical data and ... http://www.deepresearchreports.com/142870.html . --> Complete report ... 19 companies and supported with 296 tables and ...
Breaking Medicine Technology: